Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Timigutuzumab (Synonyms: TrastuzuMab-GEX, GT-MAb7.3-GEX, GEXMab73)

Catalog No. T76977 Copy Product Info
🥰Excellent
Timigutuzumab (GEXMab73) is a glyco-optimized monoclonal antibody targeting the human epidermal growth factor receptor 2 (ErbB2/HER2). Through glyco-engineering (typically afucosylation), the antibody's Fc region exhibits enhanced binding affinity for the FcγRIIIa receptors on immune effector cells, such as natural killer (NK) cells. This optimization significantly boosts Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), enabling potent tumor cell lysis even in cases with low HER2 expression levels. Timigutuzumab is designed to overcome resistance to conventional anti-HER2 therapies and provide an improved therapeutic option for solid tumors.

Timigutuzumab

Copy Product Info
🥰Excellent
Catalog No. T76977
Synonyms TrastuzuMab-GEX, GT-MAb7.3-GEX, GEXMab73

Timigutuzumab (GEXMab73) is a glyco-optimized monoclonal antibody targeting the human epidermal growth factor receptor 2 (ErbB2/HER2). Through glyco-engineering (typically afucosylation), the antibody's Fc region exhibits enhanced binding affinity for the FcγRIIIa receptors on immune effector cells, such as natural killer (NK) cells. This optimization significantly boosts Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), enabling potent tumor cell lysis even in cases with low HER2 expression levels. Timigutuzumab is designed to overcome resistance to conventional anti-HER2 therapies and provide an improved therapeutic option for solid tumors.

Timigutuzumab
Cas No. 1665274-14-5
Pack SizePriceUSA StockGlobal StockQuantity
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Timigutuzumab (GEXMab73) is a glyco-optimized monoclonal antibody targeting the human epidermal growth factor receptor 2 (ErbB2/HER2). Through glyco-engineering (typically afucosylation), the antibody's Fc region exhibits enhanced binding affinity for the FcγRIIIa receptors on immune effector cells, such as natural killer (NK) cells. This optimization significantly boosts Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), enabling potent tumor cell lysis even in cases with low HER2 expression levels. Timigutuzumab is designed to overcome resistance to conventional anti-HER2 therapies and provide an improved therapeutic option for solid tumors.
In vitro
Timigutuzumab (GEXMab73) exhibits enhanced ADCC activity against HER2-positive cells due to glyco-optimization, which increases its affinity for Fcγ receptors. Compared to non-optimized antibodies, it enables more effective tumor cell depletion at lower concentrations [1].
SynonymsTrastuzuMab-GEX, GT-MAb7.3-GEX, GEXMab73
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetErbB2
Chemical Properties
Cas No.1665274-14-5
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Timigutuzumab | purchase Timigutuzumab | Timigutuzumab cost | order Timigutuzumab | Timigutuzumab in vitro